A 5-HT Antagonist (UP 26-91) versus Codeine and Placebo in a Human Experimental Pain Study
BACKGROUND: This double-blind, randomized, crossover study compared the potential analgesic effect of the serotonin receptor antagonist UP 26-91 (50 mg, 150 mg and 300 mg) with that of codeine (100 mg) and placebo by use of different human experimental pain models.
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2000-01-01
|
| Series: | Pain Research and Management |
| Online Access: | http://dx.doi.org/10.1155/2000/842198 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567041553334272 |
|---|---|
| author | Lars Arendt-Nielsen Poul Pedersen Lars Poulsen Ole Kæseler Andersen Peter Bjerring Isabelle Coste Jorge Insuasty Søren Sindrup Asbjørn Mohr Drewes |
| author_facet | Lars Arendt-Nielsen Poul Pedersen Lars Poulsen Ole Kæseler Andersen Peter Bjerring Isabelle Coste Jorge Insuasty Søren Sindrup Asbjørn Mohr Drewes |
| author_sort | Lars Arendt-Nielsen |
| collection | DOAJ |
| description | BACKGROUND: This double-blind, randomized, crossover study compared the potential analgesic effect of the serotonin receptor antagonist UP 26-91 (50 mg, 150 mg and 300 mg) with that of codeine (100 mg) and placebo by use of different human experimental pain models. |
| format | Article |
| id | doaj-art-87cd25fc24b84e4daef94fcb3b79b19c |
| institution | Kabale University |
| issn | 1203-6765 |
| language | English |
| publishDate | 2000-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pain Research and Management |
| spelling | doaj-art-87cd25fc24b84e4daef94fcb3b79b19c2025-02-03T01:02:30ZengWileyPain Research and Management1203-67652000-01-015213514010.1155/2000/842198A 5-HT Antagonist (UP 26-91) versus Codeine and Placebo in a Human Experimental Pain StudyLars Arendt-Nielsen0Poul Pedersen1Lars Poulsen2Ole Kæseler Andersen3Peter Bjerring4Isabelle Coste5Jorge Insuasty6Søren Sindrup7Asbjørn Mohr Drewes8Center for Sensory-Motor Interaction, Aalborg University, Aalborg, DenmarkDepartment of Medicine, Aalborg Hospital, Aalborg, DenmarkDepartment of Medicine, Aalborg Hospital, Aalborg, DenmarkCenter for Sensory-Motor Interaction, Aalborg University, Aalborg, DenmarkDepartment of Dermatology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Research, UPSA Laboratories, Rueil-Malmaison, FranceDepartment of Clinical Research, UPSA Laboratories, Rueil-Malmaison, FranceDepartment of Clinical Pharmacology, Odense University, Odense, DenmarkCenter for Sensory-Motor Interaction, Aalborg University, Aalborg, DenmarkBACKGROUND: This double-blind, randomized, crossover study compared the potential analgesic effect of the serotonin receptor antagonist UP 26-91 (50 mg, 150 mg and 300 mg) with that of codeine (100 mg) and placebo by use of different human experimental pain models.http://dx.doi.org/10.1155/2000/842198 |
| spellingShingle | Lars Arendt-Nielsen Poul Pedersen Lars Poulsen Ole Kæseler Andersen Peter Bjerring Isabelle Coste Jorge Insuasty Søren Sindrup Asbjørn Mohr Drewes A 5-HT Antagonist (UP 26-91) versus Codeine and Placebo in a Human Experimental Pain Study Pain Research and Management |
| title | A 5-HT Antagonist (UP 26-91) versus Codeine and Placebo in a Human Experimental Pain Study |
| title_full | A 5-HT Antagonist (UP 26-91) versus Codeine and Placebo in a Human Experimental Pain Study |
| title_fullStr | A 5-HT Antagonist (UP 26-91) versus Codeine and Placebo in a Human Experimental Pain Study |
| title_full_unstemmed | A 5-HT Antagonist (UP 26-91) versus Codeine and Placebo in a Human Experimental Pain Study |
| title_short | A 5-HT Antagonist (UP 26-91) versus Codeine and Placebo in a Human Experimental Pain Study |
| title_sort | 5 ht antagonist up 26 91 versus codeine and placebo in a human experimental pain study |
| url | http://dx.doi.org/10.1155/2000/842198 |
| work_keys_str_mv | AT larsarendtnielsen a5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT poulpedersen a5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT larspoulsen a5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT olekæselerandersen a5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT peterbjerring a5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT isabellecoste a5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT jorgeinsuasty a5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT sørensindrup a5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT asbjørnmohrdrewes a5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT larsarendtnielsen 5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT poulpedersen 5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT larspoulsen 5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT olekæselerandersen 5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT peterbjerring 5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT isabellecoste 5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT jorgeinsuasty 5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT sørensindrup 5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy AT asbjørnmohrdrewes 5htantagonistup2691versuscodeineandplaceboinahumanexperimentalpainstudy |